Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case–control study

BMC Cardiovascular Disorders

Ji-Dung Luo¹  Cheng-Yi Hsiao²  Shuo-Ju Chiang²  Chao-Shun Chan²  Chun-Ming Shih²  Yung-Ta Kao²  Wei-Fung Bi²  Chun-Yao Huang²  Kuang-Hsing Chiang²  Jen-Hung Huang³  Ming-Hsiung Hsieh³  Hui-Yu Huang⁴  Yun-Ru Liu⁵  Chun-Hsu Pan⁶  Chieh-Hsi Wu⁷  Shu-Chen Chien⁸  Chang-Jui Chen⁸ 

[1] Bioinformatics Resource Center, The Rockefeller University, 10065, New York, NY, USA;Department of Cardiology, Taipei Medical University Hospital, 11031, Taipei, Taiwan;Department of Cardiology, Taipei Municipal Wanfang Hospital, Taipei Medical University, 11031, Taipei, Taiwan;Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, 11031, Taipei, Taiwan;Joint Biobank, Office of Human Research, Taipei Medical University, 11031, Taipei, Taiwan;PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, 11031, Taipei, Taiwan;School of Pharmacy, Taipei Medical University, 11031, Taipei, Taiwan;School of Pharmacy, Taipei Medical University, 11031, Taipei, Taiwan;School of Pharmacy, Taipei Medical University, 11031, Taipei, Taiwan;Department of Pharmacy, Taipei Medical University Hospital, 11031, Taipei, Taiwan;

关键词: Biomarker;    Circulating level;    In-stent restenosis;    miRNA;   

DOI  :  10.1186/s12872-021-01893-y

来源: Springer

【 摘 要 】

BackgroundPatients who receive percutaneous coronary intervention (PCI) have different chances of developing in-stent restenosis (ISR). To date, no predictable biomarker can be applied in the clinic. MicroRNAs (miRNAs or miRs) play critical roles in transcription regulation, and their circulating levels were reported to have potential as clinical biomarkers.MethodsIn total, 93 coronary stent-implanted patients without pregnancy, liver or renal dysfunction, malignancy, hemophilia, or autoimmune diseases were recruited in this clinical study. All recruited participants were divided into an ISR group (n = 45) and a non-ISR group (n = 48) based on their restenotic status as confirmed by cardiologists at the first follow-up visit (6 months after surgery). Blood samples of all participants were harvested to measure circulating levels of miRNA candidates (miR-132, miR-142-5p, miR-15b, miR-24-2, and miR-424) to evaluate whether these circulating miRNAs can be applied as predictive biomarkers of ISR.ResultsOur data indicated that circulating levels of miR-142-5p were significantly higher in the ISR population, and results from the receiver operating characteristic (ROC) curve analysis also demonstrated superior discriminatory ability of miR-142-5p in predicting patients’ restenotic status. In addition, circulating levels of miR-15b, miR-24-2, and miR-424 had differential expressions in participants with diabetes, hyperlipidemia, and hypertension, respectively.ConclusionsThe current study revealed that the circulating level of miR-142-5p has potential application as a clinical biomarker for predicting the development of ISR in stent-implanted patients.

【 授权许可】

CC BY